Patents by Inventor Jang-Yen Wu
Jang-Yen Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11576945Abstract: Carbamathione agent protects brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimizes the size of infarcts that develop as a result of the injury.Type: GrantFiled: January 14, 2021Date of Patent: February 14, 2023Assignee: CHS PHARMA INC.Inventor: Jang-Yen Wu
-
Publication number: 20210138021Abstract: Carbamathione agent protects brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimizes the size of infarcts that develop as a result of the injury.Type: ApplicationFiled: January 14, 2021Publication date: May 13, 2021Inventor: Jang-Yen Wu
-
Patent number: 10945986Abstract: Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent.Type: GrantFiled: March 18, 2019Date of Patent: March 16, 2021Assignee: CHS Pharma, Inc.Inventors: Jang-Yen Wu, Howard Malcolm Prentice
-
Publication number: 20210052745Abstract: Gene therapy using expression vectors containing a granulocyte colony-stimulating factor (GCSF) gene are able to protect cells in a cell-based as well as animal-based models for ischemic strokeType: ApplicationFiled: November 5, 2020Publication date: February 25, 2021Inventor: Jang-Yen Wu
-
Publication number: 20190209512Abstract: Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent.Type: ApplicationFiled: March 18, 2019Publication date: July 11, 2019Inventors: Jang-Yen Wu, Howard Malcolm Prentice
-
Patent number: 10272063Abstract: Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent.Type: GrantFiled: November 3, 2017Date of Patent: April 30, 2019Assignee: CHS Pharma, Inc.Inventors: Jang-Yen Wu, Howard Malcolm Prentice
-
Publication number: 20180055809Abstract: Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent.Type: ApplicationFiled: November 3, 2017Publication date: March 1, 2018Inventors: Jang-Yen Wu, Howard Malcolm Prentice
-
Patent number: 9827220Abstract: Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent.Type: GrantFiled: June 5, 2015Date of Patent: November 28, 2017Assignee: CHS Pharma, Inc.Inventors: Jang-Yen Wu, Howard Malcolm Prentice
-
Publication number: 20150265569Abstract: Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent.Type: ApplicationFiled: June 5, 2015Publication date: September 24, 2015Inventors: Jang-Yen Wu, Howard Malcolm Prentice
-
Patent number: 9050305Abstract: Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent.Type: GrantFiled: March 29, 2013Date of Patent: June 9, 2015Assignee: CHS Pharma, Inc.Inventors: Jang-Yen Wu, Howard Malcolm Prentice
-
Publication number: 20130259824Abstract: Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent.Type: ApplicationFiled: March 29, 2013Publication date: October 3, 2013Inventors: Jang-Yen Wu, Howard Malcolm Prentice
-
Patent number: 7723302Abstract: The invention relates to the discovery that in an animal model of Parkinson's disease (PD), administration of granulocyte colony-stimulating factor (G-CSF) to rodents having 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD restored the function of dopamine neurons. In these animals, G-CSF treatment increased the number of dopamine neurons in the substantia nigra (SN), G-CSF treatment partially restored the nigrostriatal pathway, and G-CSF restored the function of dopamine to the level before MPTP treatment. The invention also relates to the discovery that treatment of a human patient with corticobasilar ganglionic degeneration, a rare progressive neurological disorder characterized by Parkinsonism and coritcal dysfunction, with G-CSF resulted in a significant improvement in the patient's Unified Parkinson's Disease Rating Scale evaluations as well as measures of activity of daily living.Type: GrantFiled: May 1, 2008Date of Patent: May 25, 2010Assignee: Florida Atlantic UniversityInventors: Jang-Yen Wu, Dipnarine Maharaj
-
Publication number: 20080300176Abstract: The invention relates to the discovery that in an animal model of Parkinson's disease (PD), administration of granulocyte colony-stimulating factor (G-CSF) to rodents having 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD restored the function of dopamine neurons. In these animals, G-CSF treatment increased the number of dopamine neurons in the substantia nigra (SN), G-CSF treatment partially restored the nigrostriatal pathway, and G-CSF restored the function of dopamine to the level before MPTP treatment. The invention also relates to the discovery that treatment of a human patient with corticobasilar ganglionic degeneration, a rare progressive neurological disorder characterized by Parkinsonism and coritcal dysfunction, with G-CSF resulted in a significant improvement in the patient's Unified Parkinson's Disease Rating Scale evaluations as well as measures of activity of daily living.Type: ApplicationFiled: May 1, 2008Publication date: December 4, 2008Applicant: Florida Atlantic UniversityInventors: Jang-Yen Wu, Dipnarine Maharaj
-
Publication number: 20050037975Abstract: Disclosed are novel compounds and novel pharmaceutical compositions for use in medical therapy, as well as intermediates and processes for preparing such compounds. Therapeutic methods for preventing or treating glutamate-related disorders in a mammal and methods to inhibit or prevent glutamate binding in mammalian tissue are also disclosed.Type: ApplicationFiled: July 25, 2003Publication date: February 17, 2005Inventors: Morris Faiman, John Schloss, Jang-Yen Wu
-
Publication number: 20030087829Abstract: Disclosed are novel compounds and novel pharmaceutical compositions for use in medical therapy, as well as intermediates and processes for preparing such compounds. Therapeutic methods for preventing or treating glutamate-related disorders in a mammal and methods to inhibit or prevent glutamate binding in mammalian tissue are also disclosed.Type: ApplicationFiled: October 28, 2002Publication date: May 8, 2003Inventors: Morris Faiman, John V. Schloss, Jang-Yen Wu
-
Publication number: 20010031730Abstract: Disclosed are novel compounds and novel pharmaceutical compositions for use in medical therapy, as well as intermediates and processes for preparing such compounds. Therapeutic methods for preventing or treating glutamate-related disorders in a mammal and methods to inhibit or prevent glutamate binding in mammalian tissue are also disclosed.Type: ApplicationFiled: December 1, 2000Publication date: October 18, 2001Inventors: Morris Faiman, John V. Schloss, Jang-Yen Wu
-
Patent number: 6156794Abstract: A method of using a compound of formula (I) wherein R.sup.1, R.sup.2, R.sup.3, X and n have any of the meanings defined in the specification, to antagonize glutamate binding, or to treat glutamate-related disorders is provided. Novel compounds, intermediates and pharmaceutical compositions are also provided.Type: GrantFiled: September 13, 1999Date of Patent: December 5, 2000Inventors: Morris Faiman, John V. Schloss, Jang-Yen Wu